HIGH POINTvTv Therapeutics,  a clinical-stage biopharmaceutical company developing orally administered treatments for Alzheimer’s disease and diabetes, has raised $4 million in equity.

The round is capped at $9 million, with $5 million remaining to be sold, according to an SEC filing.

Based out of High Point, the firm is said to have a powerful pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases, including Alzheimer’s disease, diabetes and inflammation.

“The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts,” according to its website.

vTv did not disclose how the firm plans to spend the funds.

Since 2017, the company has raised almost $16 million in equity.